{"text": ["Perjeta", "Could", "Significantly", "Boost", "Roche\u2019s", "Revenue", "Growth", "in", "2018"], "created_at": "2018-01-10 18:37:33"}
{"text": ["Novartis", "becomes", "latest", "big-name", "collaborator", "for", "Chapel", "Hill", "company"], "created_at": "2018-01-10 17:35:10"}
{"text": ["Merck's", "Keytruda", "Combo", "Gets", "Breakthrough", "Therapy", "Status"], "created_at": "2018-01-10 16:12:43"}
{"text": ["Novartis", "Starts", "Trial", "on", "Psoriasis", "Drug", "Cosentyx", "Biosoimilar"], "created_at": "2018-01-10 14:36:02"}
{"text": ["Ignyta", "and", "Its", "Key", "Risks", "in", "2018"], "created_at": "2018-01-10 14:05:20"}
{"text": ["Why", "AbbVie", "Wants", "Imbruvica", "to", "Be", "a", "Foundation", "Therapy", "in", "Hematologic", "Oncology"], "created_at": "2018-01-10 14:00:27"}
{"text": ["Inside", "Ignyta\u2019s", "Financial", "Performance"], "created_at": "2018-01-10 12:37:55"}
{"text": ["The", "Swiss", "Stock", "Market", "Pulled", "Back", "From", "Yesterday's", "New", "High"], "created_at": "2018-01-10 12:14:00"}
